Orlistat (Xenical)
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Fatty Liver
Conditions
Fatty Liver, Hepatitis
Trial Timeline
Oct 1, 2003 โ Dec 1, 2006
NCT ID
NCT00160407About Orlistat (Xenical)
Orlistat (Xenical) is a approved stage product being developed by Roche for Fatty Liver. The current trial status is completed. This product is registered under clinical trial identifier NCT00160407. Target conditions include Fatty Liver, Hepatitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00160407 | Approved | Completed |
Competing Products
20 competing products in Fatty Liver
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 47 |
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 25 |
| GODEX + Placebo | Celltrion | Phase 3 | 77 |
| placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 52 |
| AZ compound | AstraZeneca | Phase 2 | 52 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD7503 Intervention | AstraZeneca | Phase 1 | 33 |
| metformin | Merck | Phase 2/3 | 65 |
| Efinopegdutide + Semaglutide + Placebo | Merck | Phase 2 | 52 |
| MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride | Merck | Phase 1 | 33 |
| Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL | Merck | Phase 2 | 52 |
| LYS006 + Tropifexor | Novartis | Phase 2 | 52 |
| LJN452 | Novartis | Phase 1 | 33 |
| LCQ908 + placebo | Novartis | Phase 2 | 52 |
| Xenical, Pegasys, Copegus | Roche | Approved | 85 |
| Placebo + RO5093151 | Roche | Phase 1 | 33 |
| AMG 609 + Placebo | Amgen | Phase 1 | 32 |
| Glucagon | Novo Nordisk | Pre-clinical | 22 |
| Blood samples | Novo Nordisk | Pre-clinical | 22 |
| NNC0194-0499 + NNC0194-0499 + NC0194-0499 | Novo Nordisk | Phase 1 | 32 |